Antikor Biopharma Limited
antikor.co.uk
Biologics & Biosimilars
Health Care
Biotechnology
Claim pageClaim
Follow
Overview
Connections
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
201-500
employees, estimated range
Backers
1
Imperial College London
Momentum
0/100
no fresh signals
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.
THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse…
OUR TEAM FOUNDERS Dr. Moshik Cohen-Kutner Co-Founder And CEO Linkedin Dr. Niv Bachnoff Co-Founder And CSO Linkedin BOARD OF DIRECTORS Dr…
COMPANY NEWS October 21, 2026 October 21, 2026 CureLab Appoints Markus Puhlman, M.D., MBA, to Scientific Advisory Board Oncology…
ABOUT US Overview Vision Our Leader SCIENCE Our Science Autoimmune Disease Our Platform R&D Strategy PIPELINE CAREER NEWS News&Notice…
At Oxford BioTherapeutics, we are dedicated to pioneering the next generation of oncology treatments through targeted therapies, including…
Overview
Home Technology Antibody Drug Conjugates Innovative Platform - ‘OptiLinked’ FDCs Additional Products & Applications ANT-045, Antikor’s novel FDC against cMET Commercial Investment and funding Partner Opportunities Antikor Business News / Media In the News Scientific Publications About Us Board of…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Imperial College LondonVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely